Logo image of PRX.AS

PROSUS NV (PRX.AS) Stock Fundamental Analysis

AMS:PRX - Euronext Amsterdam - NL0013654783 - Common Stock - Currency: EUR

43.245  +0.2 (+0.46%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to PRX. PRX was compared to 11 industry peers in the Broadline Retail industry. PRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PRX has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

PRX had positive earnings in the past year.
PRX had positive earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: PRX reported negative operating cash flow in multiple years.
PRX.AS Yearly Net Income VS EBIT VS OCF VS FCFPRX.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

1.2 Ratios

PRX's Return On Assets of 11.30% is amongst the best of the industry. PRX outperforms 90.91% of its industry peers.
With a Return On Equity value of 16.31%, PRX perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
PRX has a Return On Invested Capital of 0.05%. This is in the lower half of the industry: PRX underperforms 72.73% of its industry peers.
Industry RankSector Rank
ROA 11.3%
ROE 16.31%
ROIC 0.05%
ROA(3y)17.49%
ROA(5y)15.28%
ROE(3y)25.28%
ROE(5y)21.22%
ROIC(3y)N/A
ROIC(5y)N/A
PRX.AS Yearly ROA, ROE, ROICPRX.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

1.3 Margins

PRX has a Profit Margin of 132.98%. This is amongst the best in the industry. PRX outperforms 90.91% of its industry peers.
PRX's Profit Margin has declined in the last couple of years.
PRX has a worse Operating Margin (0.66%) than 81.82% of its industry peers.
With a Gross Margin value of 42.08%, PRX is not doing good in the industry: 63.64% of the companies in the same industry are doing better.
PRX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 0.66%
PM (TTM) 132.98%
GM 42.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-6.03%
PM growth 5Y-2.17%
GM growth 3Y7.78%
GM growth 5Y0.45%
PRX.AS Yearly Profit, Operating, Gross MarginsPRX.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300 400

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PRX is destroying value.
Compared to 1 year ago, PRX has more shares outstanding
PRX has more shares outstanding than it did 5 years ago.
PRX has a worse debt/assets ratio than last year.
PRX.AS Yearly Shares OutstandingPRX.AS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B
PRX.AS Yearly Total Debt VS Total AssetsPRX.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.2 Solvency

PRX has an Altman-Z score of 4.25. This indicates that PRX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.25, PRX is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
PRX has a Debt/Equity ratio of 0.33. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.33, PRX is doing good in the industry, outperforming 63.64% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Altman-Z 4.25
ROIC/WACC0.01
WACC6.97%
PRX.AS Yearly LT Debt VS Equity VS FCFPRX.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10B 20B 30B 40B 50B

2.3 Liquidity

A Current Ratio of 4.11 indicates that PRX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 4.11, PRX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
PRX has a Quick Ratio of 4.05. This indicates that PRX is financially healthy and has no problem in meeting its short term obligations.
PRX has a Quick ratio of 4.05. This is amongst the best in the industry. PRX outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 4.11
Quick Ratio 4.05
PRX.AS Yearly Current Assets VS Current LiabilitesPRX.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.02% over the past year.
PRX shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -3.41% yearly.
The Revenue has grown by 12.23% in the past year. This is quite good.
PRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.54% yearly.
EPS 1Y (TTM)22.02%
EPS 3Y6.31%
EPS 5Y-3.41%
EPS Q2Q%45.31%
Revenue 1Y (TTM)12.23%
Revenue growth 3Y2.24%
Revenue growth 5Y15.54%
Sales Q2Q%15.92%

3.2 Future

PRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.22% yearly.
PRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.63% yearly.
EPS Next Y66.43%
EPS Next 2Y41.18%
EPS Next 3Y32.14%
EPS Next 5Y8.22%
Revenue Next Year12.31%
Revenue Next 2Y13%
Revenue Next 3Y12.82%
Revenue Next 5Y12.63%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
PRX.AS Yearly Revenue VS EstimatesPRX.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2B 4B 6B 8B
PRX.AS Yearly EPS VS EstimatesPRX.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3 4

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 15.73 indicates a correct valuation of PRX.
Compared to the rest of the industry, the Price/Earnings ratio of PRX indicates a somewhat cheap valuation: PRX is cheaper than 63.64% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 28.10. PRX is valued slightly cheaper when compared to this.
With a Price/Forward Earnings ratio of 12.39, PRX is valued correctly.
Based on the Price/Forward Earnings ratio, PRX is valued a bit cheaper than the industry average as 72.73% of the companies are valued more expensively.
PRX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 20.74, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 15.73
Fwd PE 12.39
PRX.AS Price Earnings VS Forward Price EarningsPRX.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PRX is valued more expensive than 81.82% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 507.39
PRX.AS Per share dataPRX.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

PRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PRX's earnings are expected to grow with 32.14% in the coming years.
PEG (NY)0.24
PEG (5Y)N/A
EPS Next 2Y41.18%
EPS Next 3Y32.14%

2

5. Dividend

5.1 Amount

With a yearly dividend of 0.24%, PRX is not a good candidate for dividend investing.
PRX's Dividend Yield is a higher than the industry average which is at 1.51.
With a Dividend Yield of 0.24, PRX pays less dividend than the S&P500 average, which is at 2.43.
Industry RankSector Rank
Dividend Yield 0.24%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DPN/A
EPS Next 2Y41.18%
EPS Next 3Y32.14%
PRX.AS Yearly Income VS Free CF VS DividendPRX.AS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

PROSUS NV

AMS:PRX (5/6/2025, 1:40:14 PM)

43.245

+0.2 (+0.46%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustryBroadline Retail
Earnings (Last)12-02 2024-12-02
Earnings (Next)06-23 2025-06-23/amc
Inst Owners65.46%
Inst Owner ChangeN/A
Ins Owners0.74%
Ins Owner ChangeN/A
Market Cap102.88B
Analysts80.91
Price Target52.81 (22.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.24%
Yearly Dividend0.03
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.38%
PT rev (3m)6.4%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1%
EPS NY rev (3m)1.81%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.16%
Revenue NY rev (3m)-0.36%
Valuation
Industry RankSector Rank
PE 15.73
Fwd PE 12.39
P/S 19.87
P/FCF N/A
P/OCF N/A
P/B 2.44
P/tB 2.51
EV/EBITDA 507.39
EPS(TTM)2.75
EY6.36%
EPS(NY)3.49
Fwd EY8.07%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.18
BVpS17.75
TBVpS17.25
PEG (NY)0.24
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 11.3%
ROE 16.31%
ROCE 0.06%
ROIC 0.05%
ROICexc 0.06%
ROICexgc 0.07%
OM 0.66%
PM (TTM) 132.98%
GM 42.08%
FCFM N/A
ROA(3y)17.49%
ROA(5y)15.28%
ROE(3y)25.28%
ROE(5y)21.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-6.03%
PM growth 5Y-2.17%
GM growth 3Y7.78%
GM growth 5Y0.45%
F-ScoreN/A
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Debt/EBITDA 75.53
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.11
Quick Ratio 4.05
Altman-Z 4.25
F-ScoreN/A
WACC6.97%
ROIC/WACC0.01
Cap/Depr(3y)91.16%
Cap/Depr(5y)76.21%
Cap/Sales(3y)3.47%
Cap/Sales(5y)3.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.02%
EPS 3Y6.31%
EPS 5Y-3.41%
EPS Q2Q%45.31%
EPS Next Y66.43%
EPS Next 2Y41.18%
EPS Next 3Y32.14%
EPS Next 5Y8.22%
Revenue 1Y (TTM)12.23%
Revenue growth 3Y2.24%
Revenue growth 5Y15.54%
Sales Q2Q%15.92%
Revenue Next Year12.31%
Revenue Next 2Y13%
Revenue Next 3Y12.82%
Revenue Next 5Y12.63%
EBIT growth 1Y110.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year183.8%
EBIT Next 3Y58.98%
EBIT Next 5YN/A
FCF growth 1Y231.66%
FCF growth 3Y154.72%
FCF growth 5YN/A
OCF growth 1Y424.77%
OCF growth 3Y63.5%
OCF growth 5YN/A